Sandoz Receives FDA AP Status for Digoxin Supplement Application
Sandoz's application ANDA040481 for a supplement of Digoxin has received Abbreviated Approval (AP) status from the FDA.
Asset / Drug
Drug and asset intelligence for Digoxin with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.